Michaël Mingueneau

Michaël Mingueneau

Company: Biogen

Job title: Associate Director, Multiple Sclerosis Research Unit


Michael Mingueneau is an immunologist/neuroimmunologist experienced with target identification, validation and advancing drug discovery programs in the fields of Immunology, Neuroimmunology and Autoimmunity. As R&D project and group lead at Biogen, he directs a group of scientists on cross-functional project teams to develop therapeutics for the treatment for both relapsing and progressive forms of Multiple Sclerosis. Before joining the MS research unit, Michael was part of the Biogen Immunology department and led target identification and validation efforts in peripheral autoimmune indications including Sjögren’s disease, SLE and scleroderma. Before Biogen, Michael Mingueneau completed his postdoctoral training in the laboratories of Drs. C. Benoist and D. Mathis (Harvard Medical School, Boston, US) following Ph.D. studies with Dr. B. Malissen (CIML, Marseille, France). He previously developed genetically engineered mouse models and used systems biology approaches to better understand cellular differentiation of immune cells in both physiological (Immgen project, www.immgen.org) and pathological conditions (type-1 diabetes, lymphoproliferative disorders). 


Live Q&A 10:40 am

Using this opportunity to ask your expert speakers those burning questions.Read more

day: Day Two

From Early-Generation to Next-Generation Reversible BTK Inhibitors 10:10 am

A number of BTK inhibitors have been developed over the years, but strikingly not all have demonstrated the same level of efficacy in clinical trials even within the same indication, partly reflecting the complexity of the regulation of this kinase and that not all inhibitors are created equal In this presentation, we will discuss some…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.